Jon Moses, MD retweetledi
🎯 Extending the Half-Life of mAbs: Why It Matters in IBD
In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems.
🧬 Enter Fc engineering: By tweaking the Fc region of antibodies, we can achieve:
✅ Longer half-life
✅ Reduced dosing frequency
✅ Better mucosal drug retention
✅ Lower immunogenicity risk
This fun cartoon breaks down 6 key Fc engineering strategies—including YTE, LS, LALA (Remember Risankizumab! ) , and catch-and-release—with direct applications for managing IBD.
Imagine future mAbs needing only 1 injection every 4-6 months or even longer, with less immune activation and greater mucosal healing. We're not far off!
English
